TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03745001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EHP-101 Liquid single dose
Description: One single oral administration with EHP-101 liquid formulation. The doses will be ascending per cohort from 0.91 mg to 200 mg. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EHP-101 Liquid multiple doses
Description: One single daily administration with EHP-101 liquid formulation during 7 consecutive days. The doses will be ascending per cohort. Each ascending level will not exceed the tested dose levels in the single dose part of the study. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Oral liquid administration daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Oral liquid administration daily
Study: NCT00637234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 300 mg tablets, up to 600 mg three times daily
Study: NCT02194933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks
Study: NCT04039984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prime Cup
Description: Patients in this group will have the Prime cementless acetabular cup used during surgery.
Study: NCT03400462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: Nimesulide has anti-inflammatory and analgesic properties. Like other NSAIDs it inhibits the action of COX . If prostaglandins can not be further synthesized, so there is no factor able to excite local nociceptors. According to t must be taken regularly for a minimum 2 weeks to achieve appropriate blood concentration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral appliance
Description: The stabilization appliance used in this study was a removable device for maxillary arch, made of hard acrylic. Appliance was fitted over occlusal and incisal surfaces of the teeth and precisely contacted with the teeth of opposing arch. It provided canine disocclusion of the posterior teeth during eccentric movements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral appliance
Description: The stabilization appliance used in this study was a removable device for maxillary arch, made of hard acrylic. Appliance was fitted over occlusal and incisal surfaces of the teeth and precisely contacted with the teeth of opposing arch. It provided canine disocclusion of the posterior teeth during eccentric movements.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oral appliance
Description: The stabilization appliance used in this study was a removable device for maxillary arch, made of hard acrylic. Appliance was fitted over occlusal and incisal surfaces of the teeth and precisely contacted with the teeth of opposing arch. It provided canine disocclusion of the posterior teeth during eccentric movements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Equipment: acupuncture needle 0,6\*13 e.g. Dragon Medical Device, Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd)
Study: NCT02747563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test (PSA)
Description: Measurement of blood PSA levels

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood test (PSA)
Description: Measurement of blood PSA levels
Study: NCT03501173

Intervention type: OTHER
Intervention: Standard of Care
Description: Participants will not receive any intervention in this study. Participants will receive standard of care therapy.

Intervention type: OTHER
Intervention: Standard of Care
Description: Participants will not receive any intervention in this study. Participants will receive standard of care therapy.

Intervention type: OTHER
Intervention: Standard of Care
Description: Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
Study: NCT00833508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing
Description: Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.
Study: NCT00085306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon beta
Description: recombinant interferon beta
Study: NCT01297816

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mg,BD, fo three month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline
Description: 100mg
Study: NCT01357434

Intervention type: BEHAVIORAL
Intervention: Fast Food Restaurant
Description: Participants will purchase a meal at Subway and McDonald's, on different days.
Study: NCT00005090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: 10 U/m\^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
Study: NCT01312441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Ergocalciferol capsules 50,000 IU once weekly for 6 months
Study: NCT00005090

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin sulfate
Description: 10 U/m\^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
Study: NCT01312441

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth once weekly for 6 months
Study: NCT05398965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eucalyptus Oil
Description: The Eucalyptus Oil pack contains Oleum Eucalyptus citriodora, Oleum Eucalyptus globulus, and Peppermint oil, given 4 times daily for 45 minutes each frequency, applied to the mask.
Study: NCT00005090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 150/m\^2 on days -6 to -4 (4-6 days before transplant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 100 mg/kg on day -2 (2 days before transplant).
Study: NCT02523664

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00005090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Description: 375 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 25 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
Study: NCT02227017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPV solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard meal
Study: NCT02533518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rigid bronchoscopy with ultraviolet transmission

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Study: NCT01206010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants will increase varenicline dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard dose of 1.0 mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will receive the standard dose of Varenicline (14 weeks): 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and then a continuation dose of 1.0 mg twice daily. In addition to this participants will use an tailored varenicline/placebo dose up to maximum of 2.5 mg twice daily for 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: All participants will receive the standard dose of Varenicline (14 weeks): 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and then a continuation dose of 1.0 mg twice daily. In addition to this participants will use an tailored varenicline/placebo dose up to maximum of 2.5 mg twice daily for 3 weeks.
Study: NCT02955134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talcid®
Description: Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Talcid®
Description: Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.
Study: NCT00005090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: 25 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 60 mg/kg on day -4 (4 days before transplant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: 6 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine
Description: 6 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: 2 x 10\^6 CD34+ blood mononuclear cells/kg of actual body weight
Study: NCT00872924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan 100mg
Study: NCT04172519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre- and post prostatectomy supervised PMFT
Description: intervention before and after surgery, supervised exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsupervised PMFT
Description: intervention after surgery, unsupervised exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised PMFT
Description: intervention after surgery and supervised exercise
Study: NCT03115528

Intervention type: BEHAVIORAL
Intervention: Estimation of Prognosis Questionnaire
Description: Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis. Survey will take approximately 5 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Estimation of Prognosis Questionnaire
Description: Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis. Survey will take approximately 5 minutes to complete.
Study: NCT05398965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard COVID medication
Description: This standard treatment is personalized according to the severity but is not limited to standard antiviral therapy, azithromycin 500 mg a day, vitamin C 500 mg 8 hourly a day, zinc 20 mg a day, tablet of complex vitamin B, and other symptomatic treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard COVID medication
Description: This standard treatment is personalized according to the severity but is not limited to standard antiviral therapy, azithromycin 500 mg a day, vitamin C 500 mg 8 hourly a day, zinc 20 mg a day, tablet of complex vitamin B, and other symptomatic treatments.
Study: NCT05177159

Intervention type: OTHER
Intervention: The regional cerebral oxygen saturation (rSO2)
Description: Measurement of rSO2 with non-invasive near-infrared light spectrum monitor. The average, left and right frontal regions absolute rSO2 values will be collected every 30 seconds during the whole surgery until postoperative 2 hours, and the mean values will be calculated. Absolute rSO2 value and AUT (area under the threshold) send beneath the absolute threshold limits of 40%, 50% and 20%, 30% under the baseline. AUT will be calculated based on this formula: AUT (present)=AUT (past)+(rSO2 threshold-rSO2 value)×sample rate

Intervention type: OTHER
Intervention: The regional cerebral oxygen saturation (rSO2)
Description: Measurement of rSO2 with non-invasive near-infrared light spectrum monitor. The average, left and right frontal regions absolute rSO2 values will be collected every 30 seconds during the whole surgery until postoperative 2 hours, and the mean values will be calculated. Absolute rSO2 value and AUT (area under the threshold) send beneath the absolute threshold limits of 40%, 50% and 20%, 30% under the baseline. AUT will be calculated based on this formula: AUT (present)=AUT (past)+(rSO2 threshold-rSO2 value)×sample rate
Study: NCT03040661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation for atrial fibrillation.
Description: Ablation for atrial fibrillation.
Study: NCT05177159

Intervention type: OTHER
Intervention: The glial fibrillary acidic protein (GFAP)
Description: Venous blood sample will be collected and tested for plasma GFAP. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.

Intervention type: OTHER
Intervention: The glial fibrillary acidic protein (GFAP)
Description: Venous blood sample will be collected and tested for plasma GFAP. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.

Intervention type: OTHER
Intervention: The brain-derived-neurotrophic factor (BDNF)
Description: Venous blood sample will be collected and tested for plasma BDNF. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.

Intervention type: OTHER
Intervention: The brain-derived-neurotrophic factor (BDNF)
Description: Venous blood sample will be collected and tested for plasma BDNF. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
Study: NCT01672359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginkgo Synergy® and Choline
Description: 3 tablets 2 times per day with breakfast and dinner over 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OPC Synergy® and Catalyn
Description: 3 tablets 2 times per day with breakfast and dinner over 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03040661

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation for atrial fibrillation.
Description: Ablation for atrial fibrillation.
Study: NCT01556971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: 29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
Study: NCT02582710

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VASCAZEN
Description: 6 weeks treatment with an optimized formulation of omega 3 before the carotid endarterectomy

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 6 weeks treatment with a placebo before the carotid endarterectomy
Study: NCT03636867

Intervention type: OTHER
Intervention: data and specimen collection
Description: to identify laboratory, cellular and molecular determinants of clinical success after treatment, several clinical information and specimens will be collected by Authors from each patient
Study: NCT00846066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hands on training
Description: Hands on training by a pediatric dentist on preventive oral health

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web based training
Description: Web based training alone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web based training
Description: Web based training alone
Study: NCT04273412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate-intensity lifestyle intervention
Description: standardized 12- week program and would be delivered in 4 sessions (2 individual, 2 telephonic). This lifestyle modification program is a combination of diet therapy (optimum calorie), increased daily physical activity and behavioral modification (self-monitoring, stimulus control, motivational interviewing)
Study: NCT03391635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Participants will receive electroacupuncture at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TranscutaneousElectricNerveStimulation
Description: Participants will receive transcutaneous electric nerve stimulation at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
Study: NCT03305003

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spiral notebook

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Study: NCT02955134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese medicine prescription
Description: The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g.~Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
Study: NCT01550666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE
Description: MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
Study: NCT03949348

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mid-urethral sling placement using autologous rectus fascia
Description: Mid-urethral sling placement using autologous rectus fascia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mid-urethral sling placement using synthetic mesh
Description: Mid-urethral sling placement using synthetic mesh
Study: NCT01382342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg daily
Study: NCT02874326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Study: NCT01802866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU-4429
Description: Take orally once daily for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU-4429
Description: Take orally once daily for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU-4429
Description: Take orally once daily for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take orally once daily for 24 months
Study: NCT02771171

Intervention type: RADIATION
Intervention: CT Scan
Description: CT imaging
Study: NCT03266302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoadsorber for removal of cytokines
Description: Use of the hemoadsorber during cardiac surgery with CPB. Hemoadsorber is integrated into the CPB circuit according to manufacturer's recommendation.